Prosecution Insights
Last updated: April 19, 2026
Application No. 18/566,831

HERBICIDAL COMBINATIONS AND COMPOSITIONS AND METHODS FOR TREATING WEEDS USING THE SAME

Final Rejection §101§102§112
Filed
Dec 04, 2023
Examiner
LOVE, TREVOR M
Art Unit
1611
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
UPL Corporation Limited
OA Round
2 (Final)
43%
Grant Probability
Moderate
3-4
OA Rounds
3y 6m
To Grant
68%
With Interview

Examiner Intelligence

Grants 43% of resolved cases
43%
Career Allow Rate
301 granted / 703 resolved
-17.2% vs TC avg
Strong +25% interview lift
Without
With
+24.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 6m
Avg Prosecution
36 currently pending
Career history
739
Total Applications
across all art units

Statute-Specific Performance

§101
2.4%
-37.6% vs TC avg
§103
50.9%
+10.9% vs TC avg
§102
18.9%
-21.1% vs TC avg
§112
14.6%
-25.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 703 resolved cases

Office Action

§101 §102 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Acknowledgement is made to Applicant’s claims filed 01/30/2026. Claims 1-3, 5-8, 10-15, 17, and 18 are pending and are currently under consideration. Claims 4, 9, and 16 are cancelled. Rejections Maintained and Made Again in view of Applicant’s Amendments Claim Rejections - 35 USC § 101 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. Claim 17 is rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter. The claim(s) does/do not fall within at least one of the four categories of patent eligible subject matter because they are directed to “use” claims which are not a statutory class. See MPEP 2173.05(q)(I)). Response to Arguments Applicant argues in the Remarks filed 01/30/2026 that the amendment to claim 17 overcomes the 101 rejection. Applicant’s argument is not found persuasive. Specifically, “use” claims are not considered a statutory class, and therefore, the rejection under 101 is maintained. It is noted that while use claims are not a statutory class, method claims are considered a statutory class. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 17 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 17 is directed to a “use claim”, and said claim is therefore deemed to be indefinite. Response to Arguments Applicant argues in the Remarks filed 01/30/2026 that the amendment to claim 17 overcomes the 112 rejection. Applicant’s argument is not found persuasive. Specifically, the claim remains indefinite since one is unable to clearly establish the metes and bounds of the “use.” Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1-16 and 18 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Mann et al (WO 2015/094884)(IDS Reference). Mann exemplifies a composition comprising glufosinate-ammonium (which includes both the L and D enantiomer) at 256 g/L, 2,4-D-choline salt at 195 g/L, and glyphosate at 205 g/L (see entire document, for instance, page 21, last paragraph). The composition is taught as being useful for crops such as cotton, cereals, sunflowers, and sugarcane (see entire document, for instance, page 20, first paragraph) as well as for row crops, trees, and vines (see entire document, for instance, page 16, last paragraph). The composition is taught as being useful for controlling undesirable vegetation, including broadleaf grass (see entire document, for instance, paragraph bridging pages 16 and 17). The composition further comprises the excipient ammonium sulfate liquid (see entire document, for instance, page 21, last paragraph), and can further comprise additional excipients including dyes, thickening agents, and dispersing agents (see entire document, for instance, page 15, third paragraph). The composition is taught as being able to be applied to plants or fallow ground (see entire document, for instance, claim 25). The components are taught as being able to be in the form of premixes which are combined and then applied, as such, these premixes are deemed to constitute a kit. Response to Arguments Applicant argues in the Remarks filed 01/30/2026 that the amendments to claims 1 and 5 overcome the rejection under 102. Applicant’s argument is not found persuasive. Specifically, the prior art composition comprises the claimed elements, and utilizes the composition for the same purpose, namely, as an herbicidal composition. With regard to the limitation that directed to a “composition consisting essentially of L-glufosinate or a salt thereof, and a choline salt of 2,4-D,” it is noted that per MPEP 2111.03 the transitional phrase “consisting essentially of” limits the scope of a claim to the specified materials or steps “and those that do not materially affect the basic and novel characteristic(s)” of the claimed invention. In re Herz, 537 F.2d 549, 551-52, 190 USPQ 461, 463 (CCPA 1976) (emphasis in original)” however, MPEP 2111.03 also states that “[f]or the purposes of searching for and applying prior art under 35 U.S.C. 102 and 103, absent a clear indication in the specification or claims of what the basic and novel characteristics actually are, “consisting essentially of” will be construed as equivalent to “comprising.”” Applicant has failed to set forth parameters for what would materially affect the basic and novel characteristics of the claimed invention, and as such, the claims are being interpreted as utilizing open language (i.e. comprising language). Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to TREVOR M LOVE whose telephone number is (571)270-5259. The examiner can normally be reached M-F typically 6:30-3. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Bethany Barham can be reached at 5712726175. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /TREVOR LOVE/Primary Examiner, Art Unit 1611
Read full office action

Prosecution Timeline

Dec 04, 2023
Application Filed
Sep 25, 2025
Non-Final Rejection — §101, §102, §112
Jan 30, 2026
Response Filed
Feb 19, 2026
Final Rejection — §101, §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599643
USE OF GREEN COFFEE BASED COMPOSITIONS FOR IMPROVING INSULIN PROFILE
2y 5m to grant Granted Apr 14, 2026
Patent 12599695
ABSORBABLE SUTURE CONTAINING POLYDEOXYRIBONUCLEOTIDE
2y 5m to grant Granted Apr 14, 2026
Patent 12594317
TRADITIONAL CHINESE MEDICINE COMPOSITION FOR TREATING NOVEL CORONAVIRUS PNEUMONIA, PREPARATION METHOD, DETECTION METHOD, AND USE THEREOF
2y 5m to grant Granted Apr 07, 2026
Patent 12575571
1-AMINO-1-CYCLOPROPANECARBOXYLIC ACID AND METHYL JASMONATE MIXTURES AND USES THEREOF
2y 5m to grant Granted Mar 17, 2026
Patent 12575563
SURFACTANTS FOR AGRICULTURAL PRODUCTS
2y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
43%
Grant Probability
68%
With Interview (+24.9%)
3y 6m
Median Time to Grant
Moderate
PTA Risk
Based on 703 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month